Hemophilia Treatment Center (HM)
Definition
Hemophilia Treatment Centers (HTCs) receive HRSA grant funding under Section 501(a)(2) of the Social Security Act to provide comprehensive, multidisciplinary care for individuals with hemophilia and other bleeding disorders. Comprehensive HTCs provide accessible, family-centered, continuous, and coordinated care.
HTCs are eligible for 340B participation and are identified as HM in OPAIS. They are not subject to the GPO Prohibition or orphan drug exclusion. Clotting factor products—the primary medications used in hemophilia treatment—are among the most expensive drugs in the U.S. market, making 340B savings particularly significant for HTCs.
The high cost of clotting factor products and the specialized nature of hemophilia care make HTCs a unique 340B participant type with specific drug purchasing and compliance considerations.
Frequently Asked Questions
Why Hemophilia Treatment Center (HM) Matters
Clotting factor products are extremely high-cost medications. 340B savings on these products are essential for HTCs to maintain comprehensive care services for their patients. Understanding HTC-specific eligibility and compliance requirements is critical.
How Virtue 340B Uses It
Virtue 340B serves HTC clients and understands the specific compliance requirements and drug purchasing considerations for this entity type.